Hualin Chen

CAMPASS: benmelstobart + anlotinib verlengt PFS versus pembrolizumab in PD-L1+ NSCLC

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as eerstelijns treatment for gevorderd squamous n...

Durvalumab Combined With Chemotherapy and SABR Therapy in Patiënten met Oligogemetastaseerd Non-small Cell Longkanker: A Multicenter Fase 2-Studie

Ivonescimab plus chemotherapie bij EGFR-variant NSCLC: fase II